Patents by Inventor Jong Seog Ahn

Jong Seog Ahn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210030716
    Abstract: The present invention relates to a composition for preventing, alleviating or treating inflammatory diseases, comprising, as an active ingredient, an acylhydrazone derivative compound, a stereoisomer thereof or a pharmaceutically acceptable salt thereof. an acylhydrazone derivative compound, a stereoisomer thereof or a pharmaceutically acceptable salt thereof, of the present invention, effectively inhibits inflammatory cytokines and inflammatory signaling pathways, thereby effectively alleviating symptoms of inflammatory diseases such as dermatitis. Therefore, the composition according to the present invention may be effectively used for the prevention, alleviation or treatment of inflammatory diseases.
    Type: Application
    Filed: January 11, 2019
    Publication date: February 4, 2021
    Inventors: Bo Yeon KIM, Joonsung HWANG, Nak Hyun SOUNG, Jong Seog AHN, Kyung Ho LEE, Jiyun MUN, Srinivasrao GANIPISETTI, Hyunjoo CHA, Mija AHN, Hee Gu LEE, Jae-Hyuk JANG, In Ja RYOO, Sung-Kyun KO
  • Patent number: 9643959
    Abstract: The present invention relates to (E)-ethyl 2-(2-methyl-3-((2-(naphtho[2,1-b]furan-2-carbonyl)hydrazono)methyl)-1H-indol-1-yl)acetate as a novel tubulin polymerization inhibitor and a method for synthesizing the same. The compound of the present invention can inhibit mitosis and induce apoptosis and thus be used as an anticancer agent, by binding to tubulin to inhibit microtube polymerization. According to the synthesis method of the present invention, the reaction is simplified and the efficiency is 60% or higher, leading to a very high yield, thereby providing an effective synthesis method.
    Type: Grant
    Filed: April 22, 2014
    Date of Patent: May 9, 2017
    Assignee: Korea Research Institute of Bioscience and Biotechnology
    Inventors: Bo Yeon Kim, Thimmegowda N.R., Sun Ok Kim, Nak Kyun Soung, Krisada Sakchaisri, InJa Ryoo, Chan-Mi Park, Jong Seog Ahn, Jae-Hyuk Jang
  • Patent number: 9433607
    Abstract: The present invention relates to ethyl(2-methyl-3{(E)-[(naphtho[2,1-b]furan-2-ylcarbonyl)hydrazono]methyl}-1H-indole-1-yl)acetate, the novel mitosis inhibitor. The said ethyl(2-methyl-3{(E)-[(naphtho[2,1-b]furan-2-ylcarbonyl)hydrazono]methyl}-1H-indole-1-yl)acetate not only induces apoptosis by inhibiting tubulin polymerization in the course of mitosis but also displays an excellent anticancer effect in the multi-drug resistant cancer cells, so that it can be effectively used for the treatment of cell proliferative disease including various cancers.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: September 6, 2016
    Assignee: Korea Research Institute of Bioscience and Biotechnology
    Inventors: Bo Yeon Kim, Krisada Sakchaisri, Sun Ok Kim, Ramegowda Thimmegowda Naraganahalli, Nak Kyun Soung, Jong Seog Ahn, Joonsung Hwang, In Ja Ryoo, Jae-Hyuk Jang
  • Publication number: 20160102078
    Abstract: The present invention relates to (E)-ethyl 2-(2-methyl-3-((2-(naphtho[2,1-b]furan-2-carbonyl)hydrazono)methyl)-1H-indol-1-yl)acetate as a novel tubulin polymerization inhibitor and a method for synthesizing the same. The compound of the present invention can inhibit mitosis and induce apoptosis and thus be used as an anticancer agent, by binding to tubulin to inhibit microtube polymerization. According to the synthesis method of the present invention, the reaction is simplified and the efficiency is 60%, or higher, leading to a very high yield, thereby providing an effective synthesis method.
    Type: Application
    Filed: April 22, 2014
    Publication date: April 14, 2016
    Inventors: Bo Yeon KIM, Thimmegowda N.R., Sun Ok KIM, Nak Kyun SOUNG, Krisada SAKCHAISRI, InJa RYOO, Chan-Mi PARK, Jong Seog AHN, Jae-Hyuk JANG
  • Publication number: 20150182502
    Abstract: The present invention relates to ethyl(2-methyl-3{(E)-[(naphtho[2,1-b]furan-2-ylcarbonyl)hydrazono]methyl}-1H-indole-1-yl)acetate, the novel mitosis inhibitor. The said ethyl(2-methyl-3{(E)-[(naphtho[2,1-b]furan-2-ylcarbonyl)hydrazono]methyl}-1H-indole-1-yl)acetate not only induces apoptosis by inhibiting tubulin polymerization in the course of mitosis but also displays an excellent anticancer effect in the multi-drug resistant cancer cells, so that it can be effectively used for the treatment of cell proliferative disease including various cancers.
    Type: Application
    Filed: March 6, 2015
    Publication date: July 2, 2015
    Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
    Inventors: Bo Yeon Kim, Krisada Sakchaisri, Sun Ok Kim, Ramegowda Thimmegowda Naraganahalli, Nak Kyun Soung, Jong Seog Ahn, Joonsung Hwang, In Ja Ryoo, Jae-Hyuk Jang
  • Patent number: 8916602
    Abstract: The present invention relates to novel fusarisetin compounds separated from Fusarium sp. FN080326 and having an anticancer activity, and to the use thereof. In detail, novel fusarisetin compounds separated and purified from Fusarium sp. FN080326, which is in turn separated from a soil sample, have an inhibitory activity on the proliferation and transfer of cancer cells such as breast cancer cells, liver cancer cells or myeloid leukemic cells. Therefore, the compounds can be effectively used for anticancer compositions containing the compounds as active ingredients.
    Type: Grant
    Filed: July 20, 2011
    Date of Patent: December 23, 2014
    Assignee: Korea Research Institute of Bioscience and Biotechnology
    Inventors: Jong Seog Ahn, Jae-Hyuk Jang, Bo Yeon Kim, JunPhil Jang, Yukihiro Asami, Hyuncheol Oh
  • Publication number: 20130116297
    Abstract: The present invention relates to novel fusarisetin compounds separated from Fusarium sp. FN080326 and having an anticancer activity, and to the use thereof. In detail, novel fusarisetin compounds separated and purified from Fusarium sp. FN080326, which is in turn separated from a soil sample, have an inhibitory activity on the proliferation and transfer of cancer cells such as breast cancer cells, liver cancer cells or myeloid leukemic cells. Therefore, the compounds can be effectively used for anticancer compositions containing the compounds as active ingredients.
    Type: Application
    Filed: July 20, 2011
    Publication date: May 9, 2013
    Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
    Inventors: Jong Seog Ahn, Jae-Hyuk Jang, Bo Yeon Kim, JunPhil Jang, Yukihiro Asami, Hyuncheol Oh
  • Publication number: 20100159039
    Abstract: An antiviral substance including a fermentation product of garlic that is fermented by lactic acid bacteria is provided. More specifically, an antiviral agent including a fermentation product of garlic, that is fermented by lactic acid bacteria, as an active ingredient is provided. The antiviral agent including a fermentation product of garlic fermented by lactic acid bacteria is useful as a preventing or treating agent of viral infection by inhibiting viruses.
    Type: Application
    Filed: March 5, 2010
    Publication date: June 24, 2010
    Applicants: Liisna Inc., KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
    Inventors: Jong-Hwa LEE, Ji-Hyoung WOO, Jung-Sook LEE, Jong-Seog AHN
  • Publication number: 20100159038
    Abstract: The present invention relates to an antibacterial composition including a fermented garlic solution that is fermented by lactic acid bacteria. More specifically, it provides an antibacterial substance active against gram-positive and gram-negative bacteria, yeast, and antibiotic-resistant bacteria. An antibacterial composition according to the present invention that includes a fermented garlic solution that is fermented by lactic acid bacteria as an active ingredient controls the growth of bacteria or fungi, and is thereby able to prevent and treat infections thereof.
    Type: Application
    Filed: March 5, 2010
    Publication date: June 24, 2010
    Applicants: Liisna Inc., KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
    Inventors: Jong-Hwa LEE, Ji-Hyoung Woo, Ah-Rum Lee, Hyo-Bin Lim, Jung-Sook Lee, Jong-Seog Ahn
  • Publication number: 20100143514
    Abstract: An antiviral substance including a fermentation product of garlic that is fermented by lactic acid bacteria is provided. More specifically, an antiviral agent including a fermentation product of garlic, that is fermented by lactic acid bacteria, as an active ingredient is provided. The antiviral agent including a fermentation product of garlic fermented by lactic acid bacteria is useful as a preventing or treating agent of viral infection by inhibiting viruses.
    Type: Application
    Filed: December 9, 2008
    Publication date: June 10, 2010
    Applicants: Liisna Inc., KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
    Inventors: Jong-Hwa LEE, Ji-Hyoung Woo, Jung-Sook Lee, Jong-Seog Ahn
  • Publication number: 20090285920
    Abstract: The present invention relates to an antibacterial composition including a fermented garlic solution that is fermented by lactic acid bacteria. More specifically, it provides an antibacterial substance active against gram-positive and gram-negative bacteria, yeast, and antibiotic-resistant bacteria. An antibacterial composition according to the present invention that includes a fermented garlic solution that is fermented by lactic acid bacteria as an active ingredient controls the growth of bacteria or fungi, and is thereby able to prevent and treat infections thereof.
    Type: Application
    Filed: August 27, 2008
    Publication date: November 19, 2009
    Applicants: Liisna Inc., KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
    Inventors: Jong-Hwa LEE, Ji-Hyoung Woo, Ah-Rum Lee, Hyo-Bin Lim, Jung-Sook Lee, Jong-Seog Ahn
  • Patent number: 7060714
    Abstract: The invention is aimed at discovering a new type of anti-cancer compound which can exert an excellent inhibitory activity against the heparanase. A fungal strain Acremonium sp. MT70646 (KCTC 8973P) was isolated from the soil. From the culture of the isolated fungal strain, novel compounds that can inhibit both heparinase and heparanase was purified. Therefore, the present invention regards to provide a newly isolated fungal strain Acremonium sp. MT70646 (KCTC 8973P), its new products, and pharmaceutical agents such as a heparinase inhibitor, a heparanase inhibitor, a metastasis inhibitor and an angeiogenesis inhibitor all of which contain the above new compounds produced by the fungal strain as an active ingredient.
    Type: Grant
    Filed: December 19, 2000
    Date of Patent: June 13, 2006
    Assignee: Korea Research Institute of Bioscience and Biotechnology
    Inventors: Jong Seog Ahn, Bo Yeon Kim, Won Keun Oh, Tae Ick Mheen, Dae Ook Kang, Hack Ryong Ko
  • Publication number: 20030032603
    Abstract: The invention is aimed at discovering a new type of anti-cancer compound which can exert an excellent inhibitory activity against the heparanase. A fungal strain Acremonium sp. MT70646 (KCTC 8973P) was isolated from the soil. From the culture of the isolated fungal strain, novel compounds that can inhibit both heparinase and heparanase was purified. Therefore, the present invention regards to provide a newly isolated fungal strain Acremonium sp. MT70646 (KCTC 8973P), its new products, and pharmaceutical agents such as a heparinase inhibitor, a heparanase inhibitor, a metastasis inhibitor and an angeiogenesis inhibitor all of which contain the above new compounds produced by the fungal strain as an active ingredient.
    Type: Application
    Filed: June 21, 2002
    Publication date: February 13, 2003
    Inventors: Jong Seog Ahn, Bo Yeon Kim, Won Keun Oh, Tae Ick Mheen, Soon Cheol Ahn, Dae Ook Kang, Hack Ryong Ko, Hwan Mook Kim